During the past decade, LMC Clinical Research Inc. (Calgary) conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 15 clinical trials were completed, i.e. on average, 83.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 7 clinical trials were completed. i.e. 87.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "LMC Clinical Research Inc. (Calgary)" #1 sponsor was "LMC Diabetes & Endocrinology Ltd." with 7 trials, followed by "Eli Lilly and Company" with 6 trials sponsored, "Mannkind Corporation" with 5 trials sponsored, "Pfizer" with 3 trials sponsored and "Xeris Pharmaceuticals" with 3 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "LMC Clinical Research Inc. (Calgary)" #1 collaborator was "Albert Einstein College of Medicine" with 1 trials as a collaborator, "BCDiabetes.Ca" with 1 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Emory University" with 1 trials as a collaborator and "Empiristat, Inc." with 1 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "LMC Clinical Research Inc. (Calgary)" are "Type 2 Diabetes" (5 trials), "Diabetes Mellitus, Type 1" (4 trials), "Type 1 Diabetes Mellitus" (4 trials), "Cardiovascular Disease" (3 trials) and "Diabetes Mellitus, Type 2" (3 trials). Many other conditions were trialed in "LMC Clinical Research Inc. (Calgary)" in a lesser frequency.

Most popular intervention types in "LMC Clinical Research Inc. (Calgary)" are "Drug" (22 trials), "Other" (4 trials), "Device" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Insulin Degludec" (2 trials), "Insulin Glargine" (2 trials), "Insulin Lispro" (2 trials) and "Technosphere Insulin" (2 trials). Other intervention names were less common.

The vast majority of trials in "LMC Clinical Research Inc. (Calgary)" are 28 trials for "All" genders.

Currently, there are NaN active trials in "LMC Clinical Research Inc. (Calgary)". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in LMC Clinical Research Inc. (Calgary), undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in LMC Clinical Research Inc. (Calgary), 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".

LMC Clinical Research Inc. (Calgary) has several departments that took part in Clinical trials: "LMC Diabetes & Endocrinology (Markham)" - 4 trials, "LMC Diabetes & Endocrinology (Calgary)" - 2 trials